

**Pfizer Limited**

The Capital, 1802/1901,  
Plot No. C - 70, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

January 20, 2026

The Corporate Relationship Dept.  
BSE Limited  
1<sup>st</sup> Floor, P.J.Towers  
Dalal Street, Fort  
Mumbai – 400 001  
Scrip Code: 500680

The Manager, Listing Dept.  
The National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1,  
G Block Bandra-Kurla Complex, Bandra (E)  
Mumbai – 400 051  
Scrip Symbol: PFIZER

Dear Sirs,

**Sub: Intimation regarding change in Senior Management Personnel of the Company.**  
**Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform the below changes in the Senior Management Personnel of the Company:

- (i) Mr. Nilesh Pendse is appointed as Category Lead – Vaccines of the Company with effect from February 1, 2026. Mr. Pendse shall accordingly be a Senior Management Personnel of the Company effective the said date.
- (ii) Mr. Manikantan Seshadrinathan – Category Lead, Hospitals & Rare Disease will transition to another role within the Pfizer Group Companies effective February 1, 2026, and shall accordingly cease to be a Senior Management Personnel of the Company effective January 31, 2026.
- (iii) Mr. Prashant Mahalingam, Category Lead – Internal Medicine, will take up additional responsibility of the Hospitals Business of the Company and shall be redesignated as Category Lead – Internal Medicine & Hospitals, effective February 1, 2026. The profile and other details of Mr. Mahalingam were already informed to the Stock Exchanges when he was appointed as Category Lead – Internal Medicine, vide our letter dated November 5, 2024.

Additional details required to be disclosed pursuant to the SEBI Listing Regulations 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, in respect of appointment referred to (i) above are enclosed as Annexure A.

Request you to please take the above on record.

Thanking you,

Yours truly,  
For **Pfizer Limited**

**Prajeet Nair**  
**Director – Corporate Services & Company Secretary**

Encl.: A/a

CIN: [L24231MH1950PLC008311](#)

Email ID: [contactus.india@pfizer.com](mailto:contactus.india@pfizer.com)

Website: [www.pfizerltd.co.in](http://www.pfizerltd.co.in)

**Additional details pursuant to SEBI Listing Regulations 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123**

Sr.no	Particulars	Details
1.	Name	Mr. Nilesh Pendse
2.	Reasons for change	Appointment of Mr. Nilesh Pendse as Category Lead – Vaccines
3.	Date of Appointment and Term	February 1, 2026
4.	Affirmation as per List/Comp/14/2018-19 dated June 20, 2018.	Not Applicable
5.	Relationship inter-se Directors / Key Managerial Personnel / Senior Management Personnel	Mr. Nilesh Pendse is not related to any of the Directors / Key Managerial Personnel / Senior Management Personnel.
6.	Number of Shares held in the Company	Nil
7.	Brief Profile	<p>Mr. Nilesh Pendse joined Pfizer Products India Private Limited, in 2024, where he led the Oncology Business, focusing on strategic growth, market access, and stakeholder engagement to advance cancer care.</p> <p>Prior to joining Pfizer Products India Private Limited, Mr. Pendse held leadership roles at Boehringer Ingelheim and Novartis where he managed diabetes and neurosciences Divisions, with a focus on sales, marketing, and franchise operations. In addition, Nilesh comes from consulting background experience with firms such as Boston Consulting Group, Ernst &amp; Young (EY) and Accenture, where he led projects related to strategy, revenue acceleration, and business transformation.</p> <p>Mr. Nilesh Pendse holds an MBA in Marketing from Jamnalal Bajaj Institute of Management Studies and a Bachelor's degree in Electronics Engineering from the University of Mumbai.</p>